Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist

(2014) J. Hoekman et al.   Clinical Journal of the American Society of Nephrology

Endothelin Antagonists in Diabetic Nephropathy: Back to Basics

(2014) K. Chandrashekar et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

(2014) D. de Zeeuw et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Endothelin and endothelin antagonists in chronic kidney disease

(2014) Donald E Kohan et al.   KIDNEY INTERNATIONAL

A novel approach for establishing cardiovascular drug efficacy

(2014) Hiddo. J. Lambers Heerspink et al.   NATURE REVIEWS DRUG DISCOVERY

Changes in Diabetes-Related Complications in the United States, 1990–2010

(2014) Edward W. Gregg et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers

(2013) P A Smink et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

(2013) PA Smink et al.   European Journal of Preventive Cardiology

Risk prediction models: II. External validation, model updating, and impact assessment

(2012) Karel G M Moons et al.   HEART

Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD

(2012) N. Dhaun et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy

(2011) D. E. Kohan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Enrichment of Clinical Study Populations

(2010) R Temple   CLINICAL PHARMACOLOGY & THERAPEUTICS

Comparison of Different Measures of Urinary Protein Excretion for Prediction of Renal Events

(2010) H. J. Lambers Heerspink et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Avosentan for Overt Diabetic Nephropathy

(2010) J. F.E. Mann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria

(2009) R. R. Wenzel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

(2009) Michael A Weber et al.   LANCET

Defining the optimal dose of a new drug: a crucial decision

(2009) Hiddo Lambers Heerspink et al.   Nature Reviews Nephrology